Fwd: Teachers warn of asbestos danger (Channel 4)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Teachers warn of asbestos danger (Channel 4)
To: mesothelioma77@gmail.com


A teachers' union is calling for a national survey of all schools to discover the extent of asbestos use in buildings. The material was used extensively in schools built between the Second World War and the early 1980s, and an estimated 13,000 schools in the UK could contain it.

Fri, 15 Feb 2008 21:30:50 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12lm2bl83/*http%3A//www.channel4.com/news/articles/uk/teachers+warn+of+asbestos+danger/1575847
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Call for school asbestos survey (BBC News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Call for school asbestos survey (BBC News)
To: mesothelioma77@gmail.com


The government is urged to survey all schools for life-threatening asbestos.

Fri, 15 Feb 2008 19:22:43 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=125imldr9/*http%3A//news.bbc.co.uk/go/rss/-/2/hi/uk_news/education/7247516.stm
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.
To: mesothelioma77@gmail.com


[1]Xenobiotica. 2008 Mar; 38(3): 325-339
Kim YW, Kim YK, Lee JY, Chang KT, Lee HJ, Kim DK, Sheen YY

The authors investigated the pharmacokinetics and metabolism of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide (IN-1130), a novel ALK5 inhibitor, which suppresses renal and hepatic fibrosis, and also exerts anti-metastatic effects on breast cancer-bearing MMTV-cNeu mice model. Plasma half-lives of orally administered IN-1130 were 62.6 min in mice, 76.6 +/- 10.6 min in dogs, 156.1 +/- 19.3 min in rats, and 159.9 +/- 59.9 min in monkeys. IN-1130 showed a high apparent permeability coefficient (P(app)) of (45.0 +/- 2.3) x 10(-6) cm s(-1) in in vitro permeability tests in a Caco-2 cell monolayer model. The bioavailability of orally administered IN-1130 was 84.9% in dogs and 34.4% in monkeys (oral dose, 5.5 mg kg(-1)), 11.4% in rats and 8.95% in mice (oral dose, 50.3 mg kg(-1)), respectively. Orally given IN-1130 was readily distributed into liver, kidneys and lungs. The major metabolite of IN-1130 (M1) was detected in the systemic circulation of rat and mouse and was purified and tentatively identified as 3-((4-(3-hydroxyquinoxaline-6-yl)-5-(6-methylpyridine-2-yl)-1H-imidazol-2-yl)methyl)benzamide or 3-((4-(2-hydroxyquinoxalin-6-yl)-5-(6-methylpyridine-2-yl)-1H-imidazol-2-yl)methyl)benzamide. The highest levels of M1 were found in liver. The results of this study suggest that IN-1130 has the potential to serve as an effective oral anti-fibrotic drug.



___
Source: http://www.hubmed.org/display.cgi?uids=18274960
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Researchers Use Transcriptome Analysis by 454 Sequencing to Identify Tumor Specific Mutations Linked to Malignant ... (Business Wire via Yahoo!7 Finance)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Tue, Feb 26, 2008 at 4:17 AM
Subject: Researchers Use Transcriptome Analysis by 454 Sequencing to Identify Tumor Specific Mutations Linked to Malignant ... (Business Wire via Yahoo!7 Finance)
To: collegeschoolloan@gmail.com


454 Life Sciences, a part of Roche Applied Science, today announced that researchers from The International Mesothelioma Program at Brigham and Women's Hospital and Harvard Medical School in Boston have used the 454 long-read sequencing technology to characterize for the first time mutations in expressed genes unique to malignant pleural mesotheliomas (MPMs).

Mon, 25 Feb 2008 22:00:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=11g7tb43h/*http%3A//au.biz.yahoo.com/080225/43/1mfx4.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc